A Phase 3 interventional study of Tolvaptan and Placebo in Hyponatremia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 12 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-04-28.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.
Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 10th largest by enrollment, is the only one that started in 2007, is one of 9 in phase 3, and was the 3rd registered.
164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.
Browse Hyponatremia studies →None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 10 · Phase 4 7
First in 2003; this study’s year is marked. 1 started in 2007.
This study's enrollment of 57 is close to the median of 60 across 97 interventional studies indexed under Hyponatremia.
Median enrollment 55 across the 20 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Hyponatremia by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 17 studies in Hyponatremia by Otsuka Holdings Co., Ltd., this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2007, is one of 8 in phase 3, and was the 3rd registered.
Otsuka Holdings Co., Ltd.’s Hyponatremia studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing tolvaptan in Hyponatremia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Hyponatremia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Demonstrate an improvement in the composite scores of validated neurocognitive tests in elderly subjects with chronic sub-clinical (i.e., asymptomatic) hyponatremia.
Subjects will be randomized, with stratification by baseline sodium \<130 or ≥ 130 mEq/L[mmol/L] to receive either tolvaptan 15 mg tablet or matching placebo tablet at doses of 15, 30 or 60 mg for 21 days. During this period, fluid restrictions should be loosened or suspended, until the subject's response to therapy can be evaluated, typically over the first few days of therapy. Fluid restriction may be reinstituted at any time in subjects whose sodium fails to improve or worsens with study therapy. A forced-titration up to 60 mg of study drug by day 3 to 7 will be based on the subject's serum sodium Subjects entering the study with a serum sodium concentration less than 130 mEq/L[mmol/L] may be fluid restricted if necessary at the discretion of the Investigator. Subjects should be monitored closely during the first 24 hours of treatment for dosing titration. The total dosing duration will be up to 21 days (plus 3 day treatment window). Subjects will return to the clinic on Day 22 (+3 days) for assessments and will complete a follow-up visit on Day 28 (+2 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo tablet given once a day for 21 days
Drug: Placebo
Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.
Drug: Tolvaptan
15-60 mg oral tablet given once a day for 21 days.
Also known as: OPC-41061
Placebo tablet given once daily for 21 days
Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)
Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize "yes" 50 times;Choice=recognize "yes" or "no" 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right \& left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data
Time frame: baseline and Day 22
Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests
Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population
Time frame: baseline and Day 22
Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test
Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population
Time frame: baseline and Day 22
Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test
Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population
Time frame: baseline and Day 22
Change From Baseline in Overall Neurocognitive Composite Score
Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population
Time frame: baseline and Day 22
Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)
Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population
Time frame: baseline and Day 22
Change From Baseline in Postural Stability Test
Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population
Time frame: baseline and Day 22
Change From Baseline in Serum Sodium; ITT Population
Change from Baseline to Day 22 in Serum Sodium; ITT population
Time frame: Baseline and Day 22
Number of Patients With Vital Sign Abnormalities: Blood Pressure
Incidence of abnormal systolic \& diastolic blood pressure values post-baseline (abnormal systolic values: \>=180 mmHg + increase of \>=20 mmHg, \<= 90 mmHg + decrease \>=20 mmHg; abnormal diastolic values: \>=105 mmHg+increase of \>=15 mmHg, \<=50 mmHg + decrease of \>= 15 mmHg)
Time frame: 28 days
Number of Patients With Vital Sign Abnormalities: Pulse Rate
Incidence of abnormal pulse rate post-baseline \[abnormal values: \>=120 beats per minute (bpm) + increase of \>=15 bpm; \<=50 bpm + decrease of \>=15 bpm\]
Time frame: 28 days
Number of Patients With Vital Sign Abnormalities: Body Weight
Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of \>=7%)
Time frame: 28 days
Number of Patients With Vital Sign Abnormalities: Body Temperature
Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of \>=1.1 to \>=38.3 degrees Celsius)
Time frame: 28 days
Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin
Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)
Time frame: 28 days
Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)
Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)
Time frame: 28 days
Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes
Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)
Time frame: 28 days
Number of Patients With Hematology Laboratory Abnormalities: Neutrophils
Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)
Time frame: 28 days
Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)
Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)
Time frame: 28 days
Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid
Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)
Time frame: 28 days
Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol
Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)
Time frame: 28 days
Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose
Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)
Time frame: 28 days
Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium
Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)
Time frame: 28 days
Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec)
Incidence of potentially clinically significant ECG abnormalities (QT\>500 msec) post-baseline
Time frame: 28 days
Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval
Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change \> 100 msec)
Time frame: 28 days
Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec
Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)
Time frame: 28 days
Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec
Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)
Time frame: 28 days
Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment
Incidence of potentially clinically significant ECG abnormalities: ST Segment
Time frame: 28 days
Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave
Incidence of potentially clinically significant ECG abnormalities: T wave
Time frame: 28 days
Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)
Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)
Time frame: 28 days
Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia
Incidence of potentially clinically significant ECG abnormalities: arrhythmia
Time frame: 28 days
16 United States (US) sites/clinics; first subject signed informed consent on 9/11/07; last subject's final visit on 12/16/08
| Milestone | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Started | 28 | 29 |
| Completed | 27 | 26 |
| Not completed | 1 | 3 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize "yes" 50 times;Choice=recognize "yes" or "no" 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right \& left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data
| Z-score | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores) | 0.20 ± 0.61 | 0.39 ± 0.49 |
Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population
| Z-score | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests | 0.21 ± 0.86 | 0.33 ± 0.41 |
Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population
| Z-score | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test | 0.04 ± 0.36 | 0.31 ± 0.46 |
Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population
| Z-score | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test | 0.24 ± 0.75 | 0.48 ± 0.91 |
Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population
| Z-score | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Change From Baseline in Overall Neurocognitive Composite Score | 0.19 ± 0.39 | 0.30 ± 0.39 |
Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population
| Seconds | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Change From Baseline in Gait Test (Timed Get-Up-and-Go Test) | 1.06 ± 5.63 | -0.43 ± 1.54 |
Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population
| Z-score | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Change From Baseline in Postural Stability Test | 1.3 ± 4.68 | -0.35 ± 2.33 |
Change from Baseline to Day 22 in Serum Sodium; ITT population
| mEq/L | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Change From Baseline in Serum Sodium; ITT Population | 2.23 ± 3.51 | 7.04 ± 3.39 |
Incidence of abnormal systolic \& diastolic blood pressure values post-baseline (abnormal systolic values: \>=180 mmHg + increase of \>=20 mmHg, \<= 90 mmHg + decrease \>=20 mmHg; abnormal diastolic values: \>=105 mmHg+increase of \>=15 mmHg, \<=50 mmHg + decrease of \>= 15 mmHg)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Vital Sign Abnormalities: Blood Pressure | 2 | 0 |
Incidence of abnormal pulse rate post-baseline \[abnormal values: \>=120 beats per minute (bpm) + increase of \>=15 bpm; \<=50 bpm + decrease of \>=15 bpm\]
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Vital Sign Abnormalities: Pulse Rate | 0 | 0 |
Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of \>=7%)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Vital Sign Abnormalities: Body Weight | 1 | 1 |
Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of \>=1.1 to \>=38.3 degrees Celsius)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Vital Sign Abnormalities: Body Temperature | 1 | 0 |
Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin | 0 | 1 |
Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT) | 1 | 3 |
Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes | 1 | 2 |
Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Hematology Laboratory Abnormalities: Neutrophils | 2 | 0 |
Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN) | 1 | 2 |
Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid | 0 | 1 |
Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol | 0 | 2 |
Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose | 2 | 0 |
Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium | 0 | 1 |
Incidence of potentially clinically significant ECG abnormalities (QT\>500 msec) post-baseline
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec) | 1 | 0 |
Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change \> 100 msec)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval | 1 | 1 |
Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec | 3 | 4 |
Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec | 2 | 3 |
Incidence of potentially clinically significant ECG abnormalities: ST Segment
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment | 0 | 2 |
Incidence of potentially clinically significant ECG abnormalities: T wave
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave | 1 | 1 |
Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI) | 0 | 1 |
Incidence of potentially clinically significant ECG abnormalities: arrhythmia
| participants | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia | 2 | 6 |
Collected over 28 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/28 (3.6%) | 13/28 (46.4%) |
| Tolvaptan (15-60 mg) | — | 2/29 (6.9%) | 17/29 (58.6%) |
| Event | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| BradycardiaCardiac disorders | 1/28 | 0/29 |
| Abdominal adhesionsGastrointestinal disorders | 0/28 | 1/29 |
| Abdominal distensionGastrointestinal disorders | 0/28 | 1/29 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/28 | 1/29 |
| ConstipationGastrointestinal disorders | 0/28 | 1/29 |
| Large intestinal obstructionGastrointestinal disorders | 0/28 | 1/29 |
| NauseaGastrointestinal disorders | 0/28 | 1/29 |
| VomitingGastrointestinal disorders | 0/28 | 1/29 |
| Event | Placebo | Tolvaptan (15-60 mg) |
|---|---|---|
| ThirstGeneral disorders | 2/28 | 6/29 |
| PollakiuriaRenal and urinary disorders | 3/28 | 4/29 |
| Weight decreasedInvestigations | 0/28 | 4/29 |
| Oedema peripheralGeneral disorders | 3/28 | 2/29 |
| Urine output increasedInvestigations | 0/28 | 3/29 |
| DermatitisSkin and subcutaneous tissue disorders | 2/28 | 0/29 |
| DizzinessNervous system disorders | 2/28 | 2/29 |
| FatigueGeneral disorders | 2/28 | 2/29 |
| Dry MouthGastrointestinal disorders | 0/28 | 2/29 |
| NasopharyngitisInfections and infestations | 1/28 | 2/29 |
| Age, Categorical(Participants) | Placebo | Tolvaptan (15-60 mg) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 12 |
| >=65 years | 22 | 23 | 45 |
| Age Continuous(years) | Placebo | Tolvaptan (15-60 mg) | Total |
|---|---|---|---|
| Mean | 71.3 ± 9.7 | 71.1 ± 10.2 | 71.2 ± 9.9 |
| Sex: Female, Male(Participants) | Placebo | Tolvaptan (15-60 mg) | Total |
|---|---|---|---|
| Female | 19 | 15 | 34 |
| Male | 9 | 14 | 23 |
| Region of Enrollment(participants) | Placebo | Tolvaptan (15-60 mg) | Total |
|---|---|---|---|
| United States | 28 | 29 | 57 |
The record gives a start of Aug 2007, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 2 years 2 months after primary completion. A results delay was requested in Feb 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Development & Commercialization, Inc. →